Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Dicot's study results to be presented at leading scientific congress

Press release: Uppsala, December 6, 2021. The pharmaceutical company Dicot announces that the results of Dicot's drug candidate will be presented at the European Society for Sexual Medicine's (ESSM) annual congress in Rotterdam in February 2022.ESSM is the leading scientific society for sexual medicine and the annual congress in February brings together prominent researchers and doctors from around the world. Dicot and Pelvipharm have sent in an abstract with results from animal studies demonstrating the long-term effect of LIB-01. Dicot now announces that ESSM's Scientific Council,

Höegh LNG Holdings Ltd. initiates buyout offer for Höegh LNG Partners LP

HAMILTON, Bermuda, 6 December, 2021 – Höegh LNG Holdings Ltd. (“Höegh LNG”) announced today that it has submitted a non-binding proposal to the Board of Directors of Höegh LNG Partners LP (“HMLP” or the “Partnership”) pursuant to which Höegh LNG would acquire through a wholly owned subsidiary all publicly held common units of the Partnership in exchange for USD 4.25 in cash per common unit. If approved, the transaction would be effected through a merger of the Partnership with a wholly owned subsidiary of Höegh LNG.  The proposed transaction is subject to the negotiation and approval of

BioStock: Broad political support benefits DanCann Pharma

The temporary Danish Pilot Programme that allows the prescription of medical cannabis to patients has been a great success. Last week, Danish politicians agreed to extend the programme for an additional four years, while also permanently allowing companies to manufacture cannabis for medical use. The unanimous decision will benefit companies like DanCann Pharma, not least in terms of making investments in the cannabinoid sphere safer, but also by making more patients and doctors aware of the extended treatment options.Read the full article about DanCann Pharma at biostock.se: https://www.

OX2 applies for a permit to construct the Galatea-Galene offshore wind farm in the Kattegat, Sweden

Monday 6 December 12.15 CET, Non-regulatory press release.  OX2 has submitted a permit application under the Act on Sweden's Exclusive Economic Zone to construct an offshore wind farm in the Swedish economic zone off the coast of Falkenberg and Varberg.The wind farm is called Galatea-Galene and divided into two sub-areas. Galatea is located about 25 km off Falkenberg and Galene about 25 km off Varberg. The wind farm will comprise up to 101 wind turbines, with a maximum height of 340 metres. OX2 has previously applied for a separate Natura 2000 permit for the offshore wind farm. The

Aerit, ICAx, and RISE team up for drone delivery pilot in Norrtälje Municipality archipelago

STOCKHOLM, SWEDEN (December 6, 2021) - Today, Aerit announces it will pilot drone delivery services to the Swedish archipelago in collaboration with ICAx, RISE Research Institutes of Sweden, and Norrtälje municipality. The announcement follows selection of the project for funding by the Swedish Innovation Agency Vinnova via the “Drones in Service of the Climate for Autumn of 2021” call.The one-year project unites stakeholders from business, research, innovation, and government, to study the benefits of drones in last-mile transport, and to accelerate the implementation of climate-neutral

FREYR to Accompany Crown Prince of Norway on Official U.S. Visit

New York, Oslo and Luxembourg, December 6, 2021, FREYR Battery (NYSE: FREY) (“FREYR”), a developer of clean, next-generation battery cell production capacity, is pleased to announce that the CEO, Tom Einar Jensen, will participate in the delegation of His Royal Highness the Crown Prince of Norway during his official visit to New York on December 6[th] and 7[th]. FREYR’s Tom Einar Jensen and Marte Mjøs Persen, the Norwegian Minister of Petroleum and Energy, will participate in a panel discussion entitled ‘Financing the Green Transition’ alongside Idar Kreutzer, CEO of Finance Norway, Sara

Third update on cyber incident

News release from Vestas Wind Systems A/SAarhus, 06 December 2021 On 19 November 2021, Vestas discovered a cyber security incident which involved external attackers gaining unauthorised access to some of Vestas’ IT systems. Following extensive investigations, forensics, restoration activities and hardening of our IT systems and IT infrastructure together with external partners and experts, all systems are, with very few exceptions, up and running. The work and investigations are still ongoing, and Vestas still has no indication that the event has impacted customer and supply chain

Correction: R-Venture pledges its shares in 24SevenOffice Group AB

Correction of the previously disclosed press release since the information is not regarded as insider information. The MAR-label has therefore been removed from the press release.R-Venture AS pledges all of its 30 117 217 shares in 24SevenOffice Group AB as collateral security to secure an investment credit of NOK 50 million provided by Pareto Bank ASA.  The purpose of the credit is to purchase additional 24SevenOffice shares as well as re-purchasing company shares in R-Venture, as R-Venture’s primary exposure is towards 24SevenOffice.  Stian Rustad, representative of the largest

NRC Group ASA – Appointment of Chief Financial Officer

NRC Group ASA (NRC) has appointed Ole Anton Gulsvik as new Chief Financial Officer (CFO) of NRC effective from 1 March 2022. Mr. Gulsvik most recently served as CEO of Seven Seas Group, an international maritime services and logistics group, focused on global ship supply. He will succeed Dag Fladby, who will continue in the CFO role through January 31, 2021. Head of Group Finance, Rolf Berge, will  act as CFO during February 2021. Mr. Gulsvik previously held leadership and executive roles during tenure at Seven Seas Group (former Eitzen Maritime Services), where he has been

R-Venture pledges its shares in 24SevenOffice Group AB

R-Venture AS pledges all of its 30 117 217 shares in 24SevenOffice Group AB as collateral security to secure an investment credit of NOK 50 million provided by Pareto Bank ASA.  The purpose of the credit is to purchase additional 24SevenOffice shares as well as re-purchasing company shares in R-Venture, as R-Venture’s primary exposure is towards 24SevenOffice.  Stian Rustad, representative of the largest shareholder group in R-Venture AS, states; “in our opinion, the 24SevenOffice share is heavily underpriced compared to competitors, and we strongly believe in 24SevenOffice’s exciting

Azelio appoints Lars Murgård as new VP Development

Azelio appoints Lars Murgård as the new VP Development, who joins the company from Jaguar Land Rover, where he was Chief Program Engineer, Powertrain Systems Engineering. Lars has a solid background in Automotive with, among several senior positions, leading roles in Powertrain at Volvo Cars. Lars Murgård will start his role at Azelio on the seventh of December and will add knowledge and experience to lead the development of advanced system products, make them cost-effective and with the right quality, adapted for volume production with deliveries to a global market. Lars replaces Annika

IDEAL-e signs framework agreement with Absolicon to set up Production line in Italy

IDEAL-e SRl Ecosoluzioni (Mantova), has signed a framework agreement with Absolicon for the installation of a production line for the T160 Solar collector in Italy. IDEAL-E is a company specialized in designing and performing projects in energy efficiency for residential houses and facilities. The total sales value covered by the agreement is estimated at € 4-5 million plus a monthly license fee of approximately € 30/sold collector and sales of components. The framework agreement prescribes the general principles for the separate agreements to be drawn up, and the steps to be taken before a

Beneq unveils two new products to serve growing demand for ALD in 300mm and compound semiconductors respectively

BENEQ, PRESS RELEASE, December 6, 2021Beneq, a forerunner in industrial production using atomic layer deposition (ALD), has launched two new products for semiconductor device fabrication: the Transform® 300 and ProdigyTM.    Dedicated to the success of More-than-Moore device makers, Beneq revolutionized ALD cluster tools when it launched the highly successful Beneq Transform® family of products. Today, Beneq broadens its product portfolio further with two new and distinct solutions.   The Beneq Transform 300 and Prodigy were each designed in response to growing technology

Biomedical Bondings product DendroPrime for coating of metal implants show excellent biological safety properties

Press release: Biomedical Bonding’s DendroPrime is a coating that prevents soft-tissue in-growth to commercial implants inserted close to tendons and joints, improving mobility after hand surgery. Recent ISO 10993 tests performed by RISE confirms DendroPrime’s excellent biological safety properties including skin irritation and cytotoxicity results.DendroPrime is an innovative coating product that prevents clinically used medical implants from soft-tissue in-growth upon surgical insertion. In Sweden, up to 40% of all finger fractures needs to be re-operated due to complications from tissue

Reminder - Invitation to Pexip Capital Markets Day

Oslo, Norway, December 6, 2021 – Pexip Holding ASA ("Pexip", Oslo Børs Ticker: PEXIP) invites investors, analysts, media, and other stakeholders to a Capital Markets Day (CMD) on Thursday December 9, 2021, from 09:00 to 11:30 CET. As a result of the increased number of Covid cases in the Oslo region and government recommendations to avoid unnecessary travel and gatherings of people, we have decided to change the event to a purely online session. You will be able to view the webcast and ask questions to the presenters or watch the recording after the event through our webpage. The event

Minutes of the Monetary Policy Meeting held on 24 November

Monetary policy needs to give continued support to the economy for inflation to be close to the inflation target in the slightly longer term. At its monetary policy meeting on 24 November, the Executive Board of the Riksbank therefore decided to hold the repo rate unchanged at zero per cent, and to purchase bonds during the first quarter of 2022 to compensate for forthcoming principal payments in the Riksbank's asset holdings.The board members noted that economic activity is strong, and that the substantial fluctuations in global demand have resulted in bottlenecks in production. They have

Correction of date in press release: "Idogen has successfully completed the optimization of the GMP manufacturing process" sent on 06 December 2021.

The correction concerns the date in the English version of the press release entitled "Idogen has successfully completed the optimization of the GMP manufacturing process for the first clinical study with its tolerogenic cell therapy IDO 8". The press release must rightly be dated 06 December 2021, which appears from the Swedish version which was published at the same time.   The online english version of the press release has been adjusted.   For further information, please contact: Anders Karlsson, CEO, Idogen AB Phone: +46 70 918 00 10 Email: anders.karlsson@idogen.

2021 Reading trends revealed - consumers are turning their homes into havens to relax and enjoy life

The European category leader within digital magazine subscriptions, has compiled a report detailing the top magazine reading trends of 2021. It demonstrates the continued impact the pandemic is having on consumers and their interests.  The latest insights show that 210,000 digital issues were read 120 million times on the platform with spiked readership in categories such as Home & Renovation and TV, Film & Cinema. During 2021 the number of bookmarked pages increased by 46% and the majority of these pages were recipes. The increased focus on stay-at-home activities started in

Wanås Konst Announces 2022 Program – Wondrous Forms, Sustainability, and Play

In 2022 Wanås Konst Sculpture Park in Skåne is focusing on art projects that drive change and materials development with exhibitions by Danish artist Peter Linde Busk and design collective Numen/For Use. Through newly-produced works and installations, they seek sustainable alternatives and fuse important questions with playful possibilities in art projects that continue the spring exhibition theme by acclaimed children’s book illustrator Beatrice Alemagna. In June, dancer and choreographer Joanna Kotze performs as part of the Live Art program. The Art Gallery has been converted to Wanås Konst’

Cyxone presents top-line results from a phase 2 study of Rabeximod in Covid-19 patients

Cyxone (publ) today announces top-line results from a phase 2 study of Rabeximod in Covid-19 patients with moderate disease. The primary endpoint, ultimately proposed by the FDA, was to document the difference of the proportion of subjects alive and free of respiratory failure at day 28 between placebo (standard of care treatment) and Rabeximod plus standard of care. The topline data analysis showed that almost all patients were alive and free of respiratory failure at day 28 in the different treatment arms. No statistical difference between treatment arms could be observed at day 28, thus

Alimak Group Sweden AB has been gold rated by EcoVadis for its sustainability work

Alimak Group Sweden AB has received a gold rated sustainability scorecard by renowned EcoVadis. The company has been ranked the top 2% of companies rated by EcoVadis in the Manufacture of general-purpose machinery industry.EcoVadis provides the leading solution for monitoring sustainability in global supply chains. It provides sustainability score cards for how companies are performing in in four areas: Environment, labour and human rights, ethics as well as sustainable procurement. The gold rating means that Alimak Group Sweden AB scored highly in all assessment areas “We are very

Aqilion focuses on treatments for inflammatory diseases, updates company pipeline

AQILION AB (publ) has decided to expand the Alnitak program by investing resources in a project focused specifically on compounds with the potential to treat inflammatory conditions of the central nervous system (CNS). In order to prioritize projects in the company's pipeline and to make best use of the company's leading-edge expertise, Aqilion will simultaneously close the Alhena oncology project and focus exclusively on drug targets with great potential in inflammatory diseases. The goal of the Alnitak program is to develop an oral medication that specifically binds to and inhibits the

First day of trading in Tobii without the right to the distribution of shares in Tobii Dynavox

As of today, Tobii’s shares will be traded without the right to the distribution of shares in Tobii Dynavox AB (publ) (“Tobii Dynavox”). The final day of trading in Tobii shares including the right to receive shares in Tobii Dynavox was Friday, December 3, 2021. The record day for the distribution of shares in Tobii Dynavox will be tomorrow, December 7, 2021. The first day of trading in ordinary shares in Tobii Dynavox on Nasdaq Stockholm is December 9, 2021. October 25, 2021 Tobii held an Extra General Meeting where shareholders decided to distribute all the shares in Tobii Dynavox

Idogen has successfully completed the optimization of the GMP manufacturing process for the first clinical study with its tolerogenic cell therapy IDO 8

Idogen AB announces today that it has successfully maximized the antigen levels in the cell therapy IDO 8 that the body should learn to recognize and tolerate. This is considered to be an important feature in order to obtain a good treatment effect. The IDO 8 treatment is aiming to create tolerance for ongoing substitution treatment with coagulation factor VIII, a vital drug for hemophilia (hemophilia A) which in many patients is inactivated as a result of undesired immune reactions. The company will shortly submit a clinical trial application to start the first study in patients. Subject

There are no items matching the current filter
There are no more items matching the current filter
Back to top